Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
-1.48 |
-0.97 |
0.51 |
34.46% |
2024-02-27 |
2023-12 |
-1.33 |
-2.53 |
-1.2 |
-90.23% |
2024-02-27 |
2023-12 |
-1.33 |
N/A |
N/A |
N/A |
2023-11-07 |
2023-09 |
-1.52 |
N/A |
N/A |
N/A |
2023-11-07 |
2023-09 |
-1.52 |
-1.18 |
0.34 |
22.37% |
2023-08-08 |
2023-06 |
-1.67 |
-1.25 |
0.42 |
25.15% |
Date |
Firm |
Action |
From |
To |
2023-09-06 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-20 |
Citigroup |
Upgrade |
Buy |
Buy |
2023-08-15 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-08-13 |
Morgan Stanley |
Upgrade |
Equal-Weight |
Equal-Weight |
2023-08-08 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
2023-08-08 |
Barclays |
Upgrade |
Overweight |
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-28 |
AGARWAL SUNIL |
Director |
14.14K |
Stock Award(Grant) |
2024-05-28 |
BAIN LINDA C |
Director |
10.02K |
Stock Award(Grant) |
2024-03-17 |
BERKOWITZ NOAH |
Officer |
63.45K |
Stock Award(Grant) |
2024-05-28 |
CUNNINGHAM EVERETT V |
Director |
10.02K |
Stock Award(Grant) |
2024-05-28 |
KENNEDY EDWARD MOORE JR. |
Director |
52.74K |
Stock Award(Grant) |
2024-05-28 |
MORRISON BRIGGS W |
Director |
30.00K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
4.90M |
121.70M |
9.17% |
2023-06-29 |
Vanguard Group Inc |
4.52M |
112.13M |
8.45% |
2023-06-29 |
FMR, LLC |
4.40M |
109.25M |
8.23% |
2023-06-29 |
EcoR1 Capital, LLC |
4.02M |
99.72M |
7.51% |
2023-06-29 |
Avidity Partners Management, LP |
2.77M |
68.83M |
5.18% |
2023-06-29 |
Price (T.Rowe) Associates Inc |
2.69M |
66.87M |
5.04% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.43M |
35.52M |
2.68% |
2023-06-29 |
Price (T.Rowe) New Horizons Fund |
1.25M |
30.94M |
2.33% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
1.17M |
29.08M |
2.19% |
2023-08-30 |
iShares Russell 2000 ETF |
1.12M |
31.58M |
2.09% |
2023-07-30 |
Vanguard Explorer Fund, Inc. |
819.77K |
20.26M |
1.53% |
2023-06-29 |
JP Morgan Small Cap Growth Fund |
704.60K |
17.49M |
1.32% |